FOLH1 and posterior cortical atrophy: Multiple targeted and immunotherapeutic approaches are under investigation or have recently demonstrated clinical benefit in advanced PCa, ranging from PARP inhibition in BRCA1/2-mutated disease to PSMA-targeted radioligand therapy in mCRPC [172].